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Summary Serum levels of mammary serum antigen (MSA) and CA15-3 were evaluated in 135 individuals in
order to determine their single and combined value in the diagnosis and monitoring of breast cancer. Raised
MSA levels (>300IU) were found in 68% of patients with Stage I and II breast cancer compared to only 3%
having raised CA15-3 levels (>40Uml-1). Of 38 patients with Stage IV breast cancer, 95% had raised levels
of MSA and CA15-3 combined with each test individually detecting 82% of those with Stage IV disease. No
correlation was found between MSA and CA15-3 levels. Four patients being treated for breast cancer were
followed over a 5-17 week period; MSA levels correlated with disease course in 3 and CA-15 in 2. The overall
sensitivity, specificity and accuracy in detecting breast cancer were 76%, 91% and 96% for MSA; and 47%,
95% and 97% for CA15-3 respectively. When both tests were used together combined evaluation gave the
highest sensitivity (84%) and specificity (100%). MSA seems to be superior to CA15-3 for early breast cancer
diagnosis and a combination of the two tests gave the best results for metastatic disease.
A suitable test for monitoring the course or to assist in the
diagnosis of all patients with breast cancer has not yet been
described. Currently, carcinoembryonic antigen (CEA) is the
most widely used antibody based clinical assay for breast
cancer, however, this has only been of limited value, as less
than 25% of patients with localised disease and 50% of
those with metastatic disease have elevated CEA levels
(Beard & Haskell, 1986). The advent of hybridoma tech-
nology (Kohler & Milstein, 1975) has led to the description
of numerous human breast cancer-associated antigens
defined by monoclonal antibodies (Schlom et al., 1985).
Two recently developed monoclonal antibody-based assays,
detecting mammary serum antigen (MSA) and CA15-3 have
been reported to be more specific markers for breast cancer
(Stacker et al., 1987; Hayes et al., 1986).
The competitive enzyme immunoassay detecting MSA
utilizes the murine monoclonal antibody 3E1.2 (Stacker et
al., 1985a), which identifies a determinant present on a high
molecular weight glycoprotein found in the serum of patients
with breast cancer (Stacker et al., 1987). The MSA test has
been found to have sensitivity for primary and metastatic
breast cancer, with raised levels found in some other
malignant diseases but in less than 2% of the normal
population (Stacker et al., 1987). The CA15-3 immunoradio-
metric assay (Centocor, Malvern, PA.) is a sandwich assay
utilizing the monoclonal antibody 115D8 developed by
Hilkens et al. (1984) as the 'catcher' and the monoclonal
antibody DF3 developed by Kufe et al. (1984) as the
radiolabelled tracer. Preliminary reports indicate that the
main application of the CA15-3 test was in the follow-up of
patients with breast cancer (Ogawa et al., 1986). The
incidence of elevated CA15-3 levels in patients with breast
cancer has been reported as varying between 0-35% for
primary tumours and 68-100% for metastatic disease (Gang
et al., 1985; Ogawa et al., 1986; Hayes et al., 1986).
The aim of this present study was to assess the individual
and combined value of the MSA and CA15-3 tests in the
management of patients with breast cancer.
Materials and methods
Patients
Blood samples were collected at The Royal Melbourne
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Hospital and St. Andrew's Hospital, Melbourne from 88
patients with histologically confirmed breast cancer (34
collected prior to mastectomy, 38 with proven metastases
and 16 with no clinical evidence of disease), 13 patients with
histologically confirmed 'benign breast disease' (comprising 3
benign cysts; 3 fibroadenoma; 4 dysplastic disease; 2 duct
papilloma; 1 duct ectasia) and 30 apparently healthy female
blood donors (Red Cross Blood Bank, Melbourne). Blood
samples were collected, the sera separated and stored at
-20°C (where possible at -70°C). The serum samples were
coded numerically so that the diagnosis was not available at
the time of analysis. After testing the code was broken and
correlation of the results and data performed. Staging of the
patients with breast cancer was independently performed by
a clinician (JPC, ISR and JAS) following standard criteria
(Millar et al., 1981; Beahrs & Myers, 1983). Serial samples
from 4 patients on treatment for metastatic breast cancer
were also collected over a 5-17 week month period. A more
detailed description of each patient is presented in the results
section of the paper.
Assays and statistical analysis
MSA levels were determined by the enzyme immunoassay
previously described (Stacker et al., 1985b). In brief, the test
is a competitive inhibition assay using purified 3E1.2
antibody. MSA present on a solid phase immunoadsorbant
was used to bind 3E1.2 previously reacted with a 1/32
dilution of patients' sera at room temperature for 3h. After
an incubation overnight at 4°C, excess serum and antibody
was washed away and sheep anti-mouse horse-radish
peroxidase conjugate (Amersham International, UK) added
for 3h at 37°C. Assays were developed using a 2.2, azino-
di[3-ethylbenthiozoline] sulphonate (ABTS) substrate system.
An arbitrary system of inhibition units (IU) was used to
express the level of MSA in serum. A standard dilution of
3E1.2 and reference normal sera were used for calculation of
units. Levels of MSA vary between 1-10,000IU, the latter
indicating a high level of MSA present. The majority of the
normal population (-98%) have levels <300IU (Stacker et
al., 1987). CA15-3 levels were determined by means of
immunoradiometric assays kits (International CIS, Saint
Quentin-Yvelines Cedex, France) according to the protocols
provided with the kits. Correlation between CA15-3 and
MSA levels was performed using the Pearson product
moment correlation coefficient (Zar, 1974).
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Results
MSA and CA15-3 levels in serum samples
Levels of MSA and CA15-3 were determined in 131 serum
samples from normal individuals and patients with breast
tumours (Table I, Figures 1 & 2). Arbitrary cut off values of
40Uml- 1 and 300IU respectively were assigned for the
CA15-3 and MSA testing. These values were used as they
gave a 3% false positive rate (this is similar to that published
in other studies). Levels of both markers for apparently
normal females were of the expected low levels (mean levels
were 116+751IU for MSA and 18+9Uml-1 for CA15-3).
Table I illustrates the evaluation of the samples tested using
a more stringent cut off limit for MSA. Here, benign
conditions can be excluded by raising the cut off level to
400IU.
Of the 13 samples from patients with histologically
confirmed benign breast disease, only one had a slightly
elevated MSA level (388IU). None of the 13 patients had
levels ofCA15-3 >40Uml -1. Interestingly, the mean CA15-3
level seen in patients with benign breast disease was much
lower than the level of the normal subjects (see Table I).
This is in contrast to MSA levels where the reverse was the
case.
Analysis of 34 patients with clinically stage I and II breast
cancer revealed raised MSA levels (>300IU) in 68% (23/34)
whereas CA15-3 was elevated (>40Uml-1) in only 1/34
patients. The mean level for this group were 17+8Uml-1
for CA15-3 compared to 578+534IU for MSA. The mean
MSA level for this group was therefore substantially raised
when compared to that of the normal population.
Significantly, more patients with Stage III and IV breast
cancer had raised levels of both MSA and CA15-3 (Table I,
Figures 1 & 2). The levels were, in general, higher than those
found with more localized disease, with the mean MSA level
of 4381 IU and the mean CA15-3 level of 133 Uml-. Both
assays detected 82% (31/38) of patients with metastatic
disease, with most subjects having markedly raised levels in
both tests. Although there was a considerable overlap
between the two assays, 26% of patients had raised levels in
only one test.
Samples were obtained from 16 patients assessed as having
no evidence of disease, either clinically or on routine
investigation. The mean level of MSA was 310IU, and was
raised in 6 patients (37%). The CA15-3 level was not raised
in any of this group, and the mean level of 18+9Uml1
was consistent with that of normal females.
Correlation ofMSA and CA15-3 levels
MSA and CA15-3 do not recognize the same antigenic
determinants as is well illustrated by the lack of statistical
correlation between these tests in normal individuals
(r=0.215), patients with no clinical evidence of disease
(r=0.361) and in patients with Stage I and II breast cancer
(r=0.446). However, it is clear that MSA and CA15-3 levels
are often significantly raised in a large proportion of patients
with Stage III/IV breast cancer (see Figure 2). It is
interesting to note that 4 patients with advanced breast
cancer had a raised MSA level but normal CA15-3, and 5
patients had a raised CA15-3 level but normal MSA level.
This suggests that both the antigenic determinant detected by
the two tests is different, and that they may be of additive
value in the management of breast cancer patients. A
correlation was found between CA15-3 and MSA levels in
patients with metastatic disease (MSA level >500IU,
r=0.702, P<0.001), although this is probably due to the
advanced stage of disease in these patients, all or most of
whom have high antigen levels. In patients with Stage IV
disease and MSA levels <500IU there was no correlation
with the CA15-3 levels in individual patients.
MSA and CA15-3for monitoring ofdisease progress
MSA and CA15-3 levels were determined in four patients
followed over a period of 5-17 weeks. The group consisted
of three patients with Stage IV disease undergoing therapy
(A, B and C) and one patient with primary breast cancer
undergoing surgery followed by adjuvant chemotherapy (D)
(Figure 3).
Patient A A patient with rapidly progressive metastatic
breast cancer (bone, liver, lungs) not responding to chemo-
therapy whose MSA level rose over the initial one week
period and remained consistently high until the patient
succumbed. CA15-3 level was initially elevated but quickly
dropped to below the normal range and remained there.
Patient B Both MSA and CA15-3 levels remained within
the normal ranges. This patient had active, but stable metas-
tases (lymph nodes, lung) whilst receiving chemotherapy.
Patient C This patient had metastatic breast cancer (lymph
nodes, bone, lung) and had a partial response to chemo-
therapy. MSA levels fell to just outside the normal range in
8 weeks; CA15-3 levels normalized within 6 weeks. It should
be noted that the patient still had residual disease consisting
of a small pulmonary nodule at the time of the last sample.
Patient D A patient with primary breast cancer before
mastectomy showed elevated levels of both CA15-3 and
MSA. After mastectomy the patient was given adjuvant
chemotherapy for Stage II disease. During this period the
levels of both MSA and CA15-3 dropped significantly. By 6
weeks the CA15-3 level had fallen below 40Uml-1 and the
MSA level was marginally above the normal range. Over the
next 6 months, CA15-3 level remained within the normal
range and MSA levels were slightly raised despite the
absence of measurable metastatic disease.
Assay parameters
The assay parameters were determined as shown in Table II.
Specificity is defined as the fraction of a non-cancer
population not positive at the selected cut off level, whereas
sensitivity is the fraction of a cancer population positive at
Table I MSA and CAl5-3 levels in serum from normal individuals and patients with breast cancer
MSA (IU) CA15-3(Uml-1)
Number % Above % Above
Group tested Mean+s.ea 300 400 Mean+s.e. 30 40
Nornal controls 30 116+75 3 0 18+9 10 3
Benign breast disease 13 170+79 8 0 12+4 0 0
Breast cancer stage I/II 34 578+534 68 50 17+8 6 3
Breast cancer stage III/IV 38 4381 +380 82 82 133+78 82 82
No evidence ofdisease 16 310+277 37 19 18+9 19 0
Total 131
aMean +standard error.822 N.P.M. SACKS et al.
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Figure 1 Levels of MSA (a) and CA15-3 (b) in the serum of normal individuals and patients with benign breast disease, no
clinical evidence of disease (NED), premastectomy (PM) breast cancer and metastatic breast cancer (Met). Horizontal lines
indicating the respective cut off values of 300IU (MSA) and 40Uml-1 (CA15-3) are shown.
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Figure 2 Correlation of CA15-3 and MSA levels in patients
with Stage IV breast cancer. The correlation between MSA and
CA15-3 was r=0.786, P<0.001. For MSA levels <500IU no
correlation was found.
that value. The predictive value of a positive test is the
fraction of a population with a positive test result who in
fact have the cancer being tested for. The sensitivity of the
MSA test was 76%, for the CA15-3 assay 47%, and when
used in combination rose to 84%. The best specificity (100%)
and predictive value of a positive test (100%) was obtained
with a combination of the two tests.
Discussion
The recently described MSA and CA15-3 assays were
compared for their clinical usefulness in the management of
patients with breast cancer. Our results from this study
indicate that the sensitivity of the MSA test (76%) is greater
than that of CA15-3 (47%) in diagnosing breast cancer.
Using the cut off value of 300IU for MSA and 40Uml-I
for CA15-3, only 3% of the normal controls tested had
elevated levels in each test (i.e. 3% flase positive).
The assays performed on serum samples taken from 34
patients with Stage I and II disease prior to mastectomy
showed that MSA levels were raised in 23 cases (68%). Only
one patient had a raised CA15-3 level, and this patient also
had a raised MSA level, findings in agreement with the
recently reported studies in which raised MSA levels were
seen in 53-75% of Stage I and II patients (Stacker et al.,
1987) and CA15-3 was raised in only 0-35% (Gang et al.,
1985). This suggests that the MSA test may be a useful
adjunct in diagnosing early breast cancer but that CA15-3
will not.
Both CA15-3 and MSA were significantly better tests for
advanced breast cancer than for localized disease. The mean
levels of both assays were usually much higher in patients
with Stage IV cancer, having a mean MSA of 4381 IU, and
133Uml-P for CA15-3. Although both assays detected 82%
(31/38) of patients with advanced breast cancer, only 26
patients had raised levels of both. In 26% (10/38) of cases,
patients had elevated levels of one or the other marker,
resulting in a combined sensitivity of 98%. This implies that
the detection of CA15-3 and MSA involves distinctly
different antigenic determinants. Of those patients with a
previous diagnosis of breast cancer but now with no
evidence of disease, on clinical examination 37% had
elevated MSA levels, but none had a raised CA15-3 level. It
will obviously be of great interest to see whether those
patients with an elevated MSA develop detectable disease in
the near future, and if so, to accurately establish the lead-
time between elevated MSA levels and the clinical detection
of disease.
Both MSA and CA15-3 levels have been reported as useful
for monitoring breast cancer patients' response to therapy
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Figure 3 Levels of MSA (-U-) and CA15-3 (- ) in four patients (a,b, c,d) with breast cancer followed over 5-17 weeks.
The patients underwent a variety of surgical and therapeutic treatments (see Results section for a complete description). Arbitrary
cut off values of 300IU for MSA (----) and 40 Uml1 for CA15-3 (---) are indicated.
Table II Sensitivity, specificity and predictive value of MSA, and
CA15-3 for the combination of tests
MSA + and/or
Assay parametera MSAb CA15-3C CA15-3+
Sensitivityd (%) 76 47 84
Specificity' (%) 91 95 100
Predictive value' 96 97 100
aAssay parameters have beencalculated usingthe data on all patients
with breast cancer; bMSA>300IUml-1; CCA15-3 >40Uml-1;
dSensitivity=TP/(TP+FN); eSpecificity=TN/(TN+FP); 'Predictive
value=TP/(TP+FP); TP: True positive; FP: Flase positive; TN:
True negative; FN: False negative.
and surgery. The results of this study show that MSA levels
correlated with clinical course in 3 of the 4 patients
monitored prospectively and CA15-3 in two. In three
(patients B, C and D) MSA and CA15-3 levels altered in the
same fashion, although patient C, on adjuvant chemo-
therapy, had a normal CA15-3 level within two weeks of
mastectomy, whereas the MSA level remained mildly
elevated whilst on treatment. Very high MSA levels
correlated with rapidly progressive breast cancer in patient A
whilst CA15-3 levels dropped dramatically over a 4 week
period. This divergence of values further suggests that
different antigens are detected by the two tests; also, the fall
in antigen levels just prior to death is a well recognized
phenomenon (Ravry et al., 1974; Mughal et al., 1983),
perhaps related to the emergence of a new anaplastic cell
population or altered antigenic expression.
Neither MSA nor CA15-3 is entirely specific for breast
cancer. In other studies, both have been found to be
moderately raised in some benign diseases, such as cirrhosis,
hepatitis and some other malignancies such as carcinoma of
the ovary, lung and pancreas, although both have been
shown to be significantly better markers for breast cancer
than CEA (Stacker et al., unpublished data, Hayes et al.,
1986). However, in this study, only samples from healthy
blood donors and patients with histologically confirmed
benign breast disease were assayed and compared to samples
from patients with proven breast cancer. Differentiating
patients with breast cancer from normal individuals and
patients with benign breast disease is most likely to be of
concern to the treating physician. A false positive rate in the
normal controls of 3% was accepted for both assays and
those with a raised level did not subsequently have any
evidence of malignant disease. If a cut-off level of 400IU is
used for MSA a 0% false positive rate for normal controls
and benign breast disease could be achieved.
The sensitivity of MSA determination alone (76%) was far
greater than CA15-3 alone (47%), and when the two were
combined sensitivity increased to 84%. Both tests had very
high specificity (91% for MSA and 95% for CA15-3) and
predictive value of a positive test result (96% for MSA
and 97% for CA15-3). When the two assays were combined,
specificity and predictive value of a positive result rose to
100%. Of course this is only a limited comparative study
and these values for assay parameters must await
confirmation in larger trials including those patients with
non-breast diseases.
This study has shown that MSA testing should be of some
value in the diagnosing of breast cancer, as 68% of Stage I
and II patients had raised MSA levels. In advanced disease
both tests are of similar accuracy with a combination of
both tests proving additive in value with acceptable
sensitivity, specificity and predictive value of close to 100%.
We thank Miss R. Godding and Mrs J. Cameron for valuable
assistance in preparing the manuscript, and Australian Atomic
Energy Commission for providing the CA15-3 test kits.
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